Press release
Lexicon Announces Series of Presentations Relating to LX9211, Its Investigational Drug for the Treatment of Diabetic Peripheral Neuropathic Pain (DPNP)
Five upcoming scientific presentations will add to the body of evidence supporting the advancement of LX9211 into late-stage development Phase 2b dose
About this update from Lexicon Pharmaceuticals, Inc.
[{"type":"text","content":"Five upcoming scientific presentations will add to the body of evidence supporting the advancement of LX9211 into late-stage development Phase 2b dose optimization study planning underway, with initiation of dosing expected before the end of 2023, and extension to run in parallel with next-stage Phase 3 studies THE WOODLANDS, Texas, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced a series of five upcoming scientific presentations on its investigational drug LX9211, which is being evaluated in clinical trials for the treatment of diabetic peripheral neuropathic pain (DPNP). Data will be shared through four oral presentations and one poster presentation at various global Congresses. Presentations are as follows: NeuPSIG 2023 International Congress on Neuropathic Pain, Sept. 7-9; Lisbon, Portugal; Poster Presentation33rd Annual Meeting of the Diabetic Neuropathy Study Group (NeuroDiab), Sept. 28-Oct. 1; Thessaloniki, Greece; Oral Presentation59th Annual Meeting of the European Association for the Study of Diabetes (EASD), Oct. 2-6; Hamburg, Germany and online; Oral Presentation17th Annual Pain Therapeutics Summit (Arrowhead Conference), Oct. 19-20; San Diego, California; Oral Presentation2nd World Brain Disorders and Neuroscience Summit (BDNS), Nov. 9-11; Singapore and online; Oral Presentation Last month, Lexicon reiterated its plans to advance LX9211 into late-stage development in a clinical program directed towards an application for regulatory approval in DPNP. The first late-stage study will be a Phase 2b dose optimization study, with study planning underway and initiation of dosing expected before the end of 2023. The Phase 2b study includes an extension to run in parallel with planned next-stage Phase 3 studies. “We look forward to reviewing our data with medical and scientific community members who share our commitment to addressing the unmet needs of DPNP patients,” said Craig Granowitz, M.D., Ph.D., Lexicon’s senior vice president and chief medical officer. “Presentations at Congresses around the world can help build awareness of the LX9211 clinical data obtained to date and LX9211’s potential to become a new, non-opioid option for people suffering from DPNP.” LX9211 has received Fast Track designation from the U.S. Food and Drug Administration for development in DPNP. About...